17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
about
Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birthProgesterone to prevent spontaneous preterm birthPrevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerationsThe mechanical role of the cervix in pregnancyRecent advances in the prevention and management of preterm birthProgesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practiceChanges in shear wave speed pre- and post-induction of labor: a feasibility study.Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.17-Hydroxyprogesterone caproate in triplet pregnancy: an individual patient data meta-analysis.Activity restriction among women with a short cervixAssessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.The association of beta-2 adrenoceptor genotype with short-cervix mediated preterm birth: a case-control studyInadvertent P-hacking among trials and systematic reviews of the effect of progestogens in pregnancy? A systematic review and meta-analysis.Pharmacogenomics of preterm birth prevention and treatment.Vaginal progesterone on the prevention of preterm birth and neonatal complications in high risk women: A randomized placebo-controlled double-blind study.Critical appraisal of the efficacy, safety, and patient acceptability of hydroxyprogesterone caproate injection to reduce the risk of preterm birth.Comparison of Risk of Preterm Labor between Vaginal Progesterone and17-Alpha-Hydroxy-Progesterone Caproate in Women with Threatened Abortion: A Randomized Clinical Trial.Prediction of Spontaneous Preterm Birth Among Nulliparous Women With a Short Cervix.Relationship between 17-alpha hydroxyprogesterone caproate concentration and spontaneous preterm birth.Adherence to criteria for transvaginal ultrasound imaging and measurement of cervical length.Progestogens for preterm birth prevention: a systematic review and meta-analysis by drug route.Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery.A systematic review and meta-analysis of progestogen use for maintenance tocolysis after preterm labor in women with intact membranes.What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.What we have learned about best practices for recruitment and retention in multicenter pregnancy studies.Effectiveness of progesterone, cerclage and pessary for preventing preterm birth in singleton pregnancies: a systematic review and network meta-analysis.What we have learned about the design of randomized trials in pregnancy.Universal cervical length screening for singleton pregnancies with no history of preterm delivery, or the inverse of the Pareto principle.Cervical Evaluation: From Ancient Medicine to Precision Medicine.Characteristics of participants in peripartum interventional research.Transvaginal sonographic evaluation of cervical length in the second trimester of asymptomatic singleton pregnancies, and the risk of preterm delivery.Does the rate of cervical shortening after cerclage predict preterm birth?Effect of cervical cerclage on rate of cervical shortening.The capacity of mid-pregnancy cervical length to predict preterm birth in low-risk women: a national cohort study.Repeated cervical length measurements for the verification of short cervical length.Implementing universal cervical length screening in asymptomatic women with singleton pregnancies: challenges and opportunities.Cervical funneling or intra-amniotic debris and preterm birth among nulliparous women with a midtrimester cervical length less than 30 mm.Screening and treatment for short cervical length in pregnancy: a physician survey in the United States.Twin PregnanciesPreterm Labor and Birth Management: Recommendations from the European Association of Perinatal Medicine.
P2860
Q24200953-0914E6ED-F59A-4592-86C5-F460462E55DBQ26827262-BCD68064-F780-4E38-92B5-D2E571B55A18Q27024142-182FE836-73BA-42F9-A617-E7AE9832C6AEQ27310144-B2AB4A09-B8C4-4736-ABB3-3192C1E07D2EQ28087299-B27631A0-7D2E-4D2B-864A-82547F08AC2BQ28654984-0DC31384-2E56-42E0-BD6A-0DBB531833A1Q30380576-10E60FF4-C224-49C4-B57F-DBEEABDC0A99Q30702434-9BE6D9BC-1983-4B75-9CAE-CBE8EAC6E618Q31031937-DEB3A5FE-6F25-4074-A72C-D710BC383F80Q33603575-7C175A2F-73D4-48A7-805F-98FD87CE01C2Q34999911-A5480A9E-2DD9-4F7B-B529-3CCDD38458F4Q35868184-66F94963-53BD-40F6-A194-12FF6D6C4FC1Q36314361-9012D57E-3182-4F9C-A027-3F05CE0C8683Q36510414-FC9AEB10-FCC1-4E58-8C18-4D879DB3F48DQ37010395-F17FE91D-8B93-455D-BAFE-D343D9D65F84Q37021150-44CE6543-145F-4C19-AE17-9596C80F54CCQ37101647-DB183E07-ECF4-4CF9-AE92-807C435299B0Q37378467-51E51DEF-C746-45FF-B076-BE6B15FDAF26Q37588374-01A059BA-BB50-4C92-8C8D-5C88E794C388Q37671996-2F052CDF-8D73-4165-8BFB-50E924CF0ACAQ38093437-95DCC0C6-786C-4902-8E26-4FAF21EEE9FFQ38200106-7DF41F1A-F4CB-4A55-9CD1-FDA132FBFA99Q38613264-04931F25-4549-47F1-B6BA-66F24FD324EFQ38815241-DFBBE020-45F8-46BF-B458-6F9C6D14EE9DQ38833449-A932A72D-9B58-411F-A17D-06EC98B555C5Q38851004-85180043-B2FD-4F69-AE09-CA5DBE45E8B4Q38877043-C2DE37ED-1B94-44C2-9566-851C53B878AFQ38998548-12F46CC6-2AC1-4F1F-AC63-140DB0DE48D6Q39359640-EF617499-8E67-4755-AFBB-11563974A54DQ41034840-8E26FC77-FC00-4E4C-8CE1-B6F43154BFFFQ41320451-14586D6D-0EEE-4B04-BC35-C673DBD1FC44Q41356145-4652578A-A358-4C7B-AB62-AB51C0F908CAQ41477327-8B28DD5C-FC2F-4D03-8326-C4DEC561C053Q41521419-BE34D5CB-EB9D-4C7E-9A85-0CB3667792C9Q48015198-719A24C2-1F5D-4A09-BA13-FA5BD386354AQ48126369-909686F8-AF06-454C-AC87-53B416981C24Q48271905-2657BD1C-89E6-430A-AF2E-D00A5ACA56ADQ48360833-A4FF14C6-2F79-4137-AD6B-56B65A02D9CDQ53101601-339DAB69-31F8-4BF5-ABEF-9E878D609260Q53111929-9B9455DF-FB61-4108-B560-8BB6E0FF421E
P2860
17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@ast
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@en
type
label
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@ast
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@en
prefLabel
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@ast
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@en
P2093
P2860
P50
P1476
17 alpha-hydroxyprogesterone c ...... rvical length less than 30 mm.
@en
P2093
Alan T N Tita
Brian M Mercer
Elizabeth A Thom
George R Saade
J Peter Van Dorsten
Jay D Iams
John M Thorp
Jorge E Tolosa
Kenneth J Leveno
M Sean Esplin
P2860
P304
P356
10.1016/J.AJOG.2012.09.013
P407
P50
P577
2012-09-17T00:00:00Z